SCHEMBL1933759

SCHEMBL1933759

CCCCOP(=O)(OCCCC)OCC[N+](C)(C)C

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.71
LMNA P02545 2/20 0.62
AKT1 P31749 2/20 0.62
ESR1 P03372 1/20 0.62
ADORA3 P0DMS8 1/20 0.62
CDC25A P30304 1/20 0.62
AGTR1 P30556 1/20 0.62
ADRA1A P35348 1/20 0.62
KCNH2 Q12809 1/20 0.62
TSHR P16473 1/20 0.55
PRKD3 O94806 1/20 0.44
PRKCG P05129 1/20 0.44
PRKCB P05771 1/20 0.44
PRKCA P17252 1/20 0.44
PRKCH P24723 1/20 0.44
PRKCI P41743 1/20 0.44
PRKCE Q02156 1/20 0.44
PRKCQ Q04759 1/20 0.44
PRKCZ Q05513 1/20 0.44
PRKCD Q05655 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5822144 0.92 LMNA (0.74) CYP3A4LMNAAKT1ESR1ADORA3
SCHEMBL29060954 0.92 LMNA (0.74) CYP3A4LMNAAKT1ESR1ADORA3
SCHEMBL22721395 0.92 LMNA (0.74) CYP3A4LMNAAKT1ESR1ADORA3
SCHEMBL17817502 0.90 CYP3A4 (0.57) CYP3A4LMNAAKT1ESR1ADORA3
SCHEMBL27641196 0.87 LMNA (0.68) CYP3A4LMNAAKT1ESR1ADORA3
SCHEMBL3828412 0.87 ADRA1A (0.48) CYP3A4LMNAAKT1ESR1ADORA3
Cetrimonium SCHEMBL28250740 0.86 CYP3A4 (0.63) CYP3A4LMNAAKT1ESR1ADORA3
SCHEMBL27895927 0.84 CYP3A4 (1.00) CYP3A4TSHRSMN1; SMN2
SCHEMBL1020179 0.84 CYP3A4 (1.00) CYP3A4TSHRSMN1; SMN2
SCHEMBL18570 0.84 CYP3A4 (1.00) CYP3A4TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12551441-B2 Water soluble silicon-containing granulate BIO MINERALS NV (BE) 2026-02-17 US claimed
US-20240408130-A1 Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps BIO MINERALS N.V. (BE) 2024-12-12 US claimed
US-11878031-B2 Silicic acids for use in the treatment of periodontitis BIO MINERALS N.V. (BE) 2024-01-23 US claimed
US-20220008454-A1 Silicic Acids for Use in the Treatment of Periodontitis BIO MINERALS N.V. (BE) 2022-01-13 US claimed
CN-113226328-A Silicic acid for treating periodontitis 生物矿物股份有限公司 2021-08-06 CN claimed
WO-2020070300-A1 SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS BIO MINERALS N.V. (BE) 2020-04-09 WO claimed
EP-3632449-A1 SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS Bio Minerals N.V. (BE) 2020-04-08 EP claimed
US-12551441-B2 Water soluble silicon-containing granulate BIO MINERALS NV (BE) 2026-02-17 US disclosed
US-20240408130-A1 Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps BIO MINERALS N.V. (BE) 2024-12-12 US disclosed
US-11878031-B2 Silicic acids for use in the treatment of periodontitis BIO MINERALS N.V. (BE) 2024-01-23 US disclosed
US-20220143078-A1 Combination of Silicon and Magnesium for the Prevention and Treatment of Muscle Cramps BIO MINERALS N.V. (BE) 2022-05-12 US disclosed
US-20220008454-A1 Silicic Acids for Use in the Treatment of Periodontitis BIO MINERALS N.V. (BE) 2022-01-13 US disclosed
CN-113853202-A Silicon-magnesium combination for preventing and treating muscle spasm 生物矿物股份有限公司 2021-12-28 CN disclosed
EP-3650011-A1 WATER SOLUBLE SILICON-CONTAINING GRANULATE Bio Minerals NV (BE) 2020-05-13 EP disclosed
WO-2020070300-A1 SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS BIO MINERALS N.V. (BE) 2020-04-09 WO disclosed
EP-3632449-A1 SILICIC ACIDS FOR USE IN THE TREATMENT OF PERIODONTITIS Bio Minerals N.V. (BE) 2020-04-08 EP disclosed
US-9289381-B2 Stabilization and storage of biological pharmaceutical compositions THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) 2016-03-22 US disclosed
US-20130089912-A1 METHODS AND COMPOSITIONS FOR THE STABILIZATION OF BIOLOGIC MATERIAL THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE 2013-04-11 US disclosed
US-20120230944-A1 STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-09-13 US disclosed
WO-2011069037-A2 STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS THE UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE (US) 2011-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12551441-B2 Water soluble silicon-containing granulate SI, GIPR, VIP CYP3A4 2169/4885LMNA 1265/4885AKT1 3666/4885
US-20120230944-A1 STABILIZATION AND STORAGE OF BIOLOGICAL PHARMACEUTICAL COMPOSITIONS IL2, IL2RA, IL36G CYP3A4 4089/4885LMNA 2050/4885AKT1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.